In vivo data assessment (animal)

Low-cost therapeutics/

Vaccine research

Therapeutics

development and evaluation under a
CFR part 404, as well as for further
licensing for commercial development
utilized in vaccine research.

Norovirus infections. Outbreaks of
delivered single chain antibody fragments
(also called VHH) are small,
recombinant monoclonal antibodies of
15 kDa (“nanobodies”) with several
advantages over conventional
antibodies. The antibodies that were
derived from llamas showed strong
neutralizing activity against Norovirus
in in vitro assays. These nanobodies
may have application as
immunoprophylaxis to protect
individuals from infections or as a
possible treatment for infected
individuals, or can be used to develop
a diagnostic for detection of norovirus
infections, and may be potentially
used in vaccine research.

This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
development and evaluation under a
research collaboration.

Potential Commercial Applications:

- Therapeutics
- Diagnostics
- Vaccine research

Competitive Advantages:

- Ease of manufacture
- Potent neutralizing activity
- Potential cross-reactivity
- Low-cost therapeutics/
immunoprophylaxis

Development Stage:

- In vivo data assessment (animal)

Inventors: Lisbeth Kim Green (NIAID),
Karin Bok (NIAID), Stanislav
Sosnovtsev (NIAID), Marina Bok (EM),
Pamela Aguilar (EM), Lorena
Garaicoechea (EM), and Viviana Parreno
(EM).

Publications: Garaicoechea L. et al.,
“Llama nanobodies with therapeutic
potential against human norovirus
diarrhea,” PLoS One. 2015 Aug
12;10(8):e0133665. doi:10.1371/
journal.pone.0133665. eCollection 2015.
[PMID 26267898].

Intellectual Property: HHS Reference
No. E–136–2013–0–U.S. Provisional
Application No. 61/821,354, filed May
9, 2013; PCT Application No. PCT/
US2014/037520, filed May 9, 2014;
European Application No. 14727696.8,
filed May 9, 2014 (pending); U.S.
Application No. 14/889,774, filed
November 6, 2015 (pending); and
Argentine Application No.
20140101882, filed May 9, 2014
(pending).

Licensing Contact: Peter Soukas, J.D.,
301–594–8730; peter.soukas@nih.gov.

Collaborative Research Opportunity:
The National Institute of Allergy and
Infectious Diseases is seeking statements
of capability or interest from parties
interested in collaborative research to
further develop, evaluate or
commercialize for development of a
therapeutic, diagnostic or vaccine for
Norovirus infections. For collaboration
opportunities, please contact Peter
Soukas, J.D., 301–594–8730;
peter.soukas@nih.gov.

Dated: February 8, 2017.

Suzanne Frishbe,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.

FOR FURTHER INFORMATION CONTACT: Glen
Nuckolls, Ph.D., by email to nuckollg@ninds.nih.gov.

SUPPLEMENTARY INFORMATION: The
Muscular Dystrophy Coordinating Committee (MDCC) is a federal advisory
commitee established in accordance
with the Muscular Dystrophy
Community Assistance, Research, and
Education Amendments of 2001 (MD–
CARE Act; Pub. L. 107–84). The MD–
CARE Act was reauthorized in 2008 by
Pub. L. 110–361, and again in 2014 by
Pub. L. 113–166. The MD–CARE Act
specifies that the committee
membership be composed of 2/3
governmental agency representatives
and 1/3 public members. We are seeking
nominations for four non-federal, public
members at this time, due to turnover of
committee membership. Nominations
will be accepted between February 17
and March 17, 2017.

Who is Eligible: Nominations are
encouraged for new or reappointment of
non-federal public members who can
provide the public and/or patient
perspectives to discussions of issues
considered by the Committee. Self-
nominations and nominations of other
individuals are both permitted. Only
one nomination per individual is
required. Multiple nominations for the
same individual will not increase
likelihood of selection. Non-federal,
public members may be selected from
the pool of submitted nominations or
other sources as needed to meet
statutory requirements and to form a
balanced committee that represents the
diversity within the muscular dystrophy
communities. Nominations are
especially encouraged from leaders or
representatives of muscular dystrophy
research, advocacy, or service
organizations, individuals with
muscular dystrophy or their parents or
guardians. In accordance with White
House Office of Management and
Budget guidelines (FR Doc. 2014–
19140), federally-registered lobbyists are
not eligible.

Committee Composition: The
Department strives to ensure that the
membership of HHS Federal advisory
commitees is fairly balanced in terms of
points of view represented and the
committee’s function. Every effort is
made to ensure that the views of all
genders, all ethnic and racial groups,
and people with disabilities are
represented on HHS Federal advisory
committees and, therefore, the
Department encourages nominations of
qualified candidates from these groups.
The Department also encourages
gender, geographic diversity in the composition of the Committee. Appointment to this

DEPARTMENT OF HEALTH AND
HUMAN SERVICES

National Institutes of Health

National Institute of Neurological Disorders and Stroke, Muscular
Dystrophy Coordinating Committee
Call for Committee Membership
Nominations

SUMMARY: The Office of the Secretary of the
Department of Health and Human Services (HHS) is seeking
nominations for an individual to serve as a
nonfederal public member on the
Muscular Dystrophy Coordinating
Committee.

DATES: Nominations are due by 5 p.m.
EST on March 17, 2017.

ADDRESSES: Nominations must be sent to Glen Nuckolls, Ph.D., by email to
nuckollg@ninds.nih.gov.
Committee shall be made without discrimination on the basis of age, race, ethnicity, gender, sexual orientation, disability, and cultural, religious, or socioeconomic status. Requests for reasonable accommodation to enable participation on the Committee should be indicated in the nomination submission.

Member Terms: Non-Federal public members of the Committee serve for a term of 3 years, and may serve for an unlimited number of terms if reappointed. Members may serve after the expiration of their terms, until their successors have taken office.

Meetings and Travel: As specified by Pub. L. 113–166, the MDCC “shall meet no fewer than two times per calendar year.” Travel expenses are provided for non-Federal public Committee members to facilitate attendance at in-person meetings. Members are expected to make every effort to attend all full committee meetings, twice per year, either in person or via remote access. Participation in relevant subcommittee, working and planning group meetings, and workshops, is also encouraged.

Submission Instructions and Deadline: Nominations are due by 5 p.m. EST on March 17, 2017, and should be sent to Glen Nuckolls, Ph.D., by email to nuckollg@ninds.nih.gov.

Nominations must include contact information for the nominee, a current curriculum vitae or resume of the nominee and a paragraph describing the qualifications of the person to represent some portion(s) of the muscular dystrophy research, advocacy and/or patient care communities.

More information about the MDCC is available at https://mdcc.nih.gov/.


Walter J. Koroshetz,
Director, National Institute of Neurological Disorders and Stroke, National Institutes of Health.

[FR Doc. 2017–03018 Filed 2–14–17; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Genetic Variation and Evolution Study Section, February 16, 2017, 08:00 a.m. to February 17, 2017, 07:00 p.m., Renaissance M Street Hotel, 1143 New Hampshire Avenue NW, Washington, DC 20037 which was published in the Federal Register on January 23, 2017, 82 FR 7642.

The meeting will be held on 02/17/2017 instead of 02/16/2017–02/17/2017. The meeting time and location remains the same. The meeting is closed to the public.


David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2017–03012 Filed 2–14–17; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Biomedical Imaging and Bioengineering; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Biomedical Imaging and Bioengineering Special Emphasis Panel; K Award—R13 Review Meeting (2017/05).

Date: March 9, 2017.

Time: 10:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.


(Disclosure of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)


Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2017–03014 Filed 2–14–17; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Microbiology, Infectious Diseases and AIDS Initial Review Group; Microbiology and Infectious Diseases B Subcommittee MID–B March 2017.

Date: March 6–7, 2017.

Time: 8:30 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Marriott Courtyard Gaithersburg Washingtonian Center, 204 Boardwalk Place, Gaithersburg, MD 20878.

Contact Person: Ellen S. Buscko, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institutes of Health/NIAID, 6700B Rockledge Drive, MSC 7616, Bethesda, MD 20892–7616, 301–451–2676, ebuczko1@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)


Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2017–03014 Filed 2–14–17; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The invention listed below is owned by an agency of the U.S. Government and is available for